Video

Education and Teamwork Are Key in the Treatment of MPNs

At the 2019 MPN Heroes® event Tammy Matuska, B.S.N., RN, known as the "lifeline to patients," was honored for her outstanding work for patients with MPN.

One of the nine honorees at the 2019 MPN Heroes® event, Tammy Matuska, B.S.N., RN, is known as “a lifeline to patients.” While she spends her days as a nurse coordinator at the Washington University School of Medicine in St. Louis, Missouri, Matuska strives to find new treatments and provide education, emotional aid and care for patients with a rare group of blood cancers known as myeloproliferative neoplasms, or MPNs: polycythemia vera, essential thrombocythemia, and myelofibrosis.

In addition to helping her patients with scheduling and paperwork, Matuska works after hours to ensure that her patients have access to proper care. She’s even spearheaded the organization of an informational dinner for patients and their families and is in the process of creating a support group for people with MPNs.

In an interview at CURE® magazine’s seventh annual event on Dec. 6 in Orlando, Florida, Matuska explained why education and teamwork are key to caring for those in the MPN community.

“I’m part of a team. It takes a lot of people to take care of these patients. We have research coordinators, clinic nurse coordinators, lab researchers; we all work as a team together on a cure for these MPNs and to take care of these patients,” Matuska said.

“Our community is very small. I like to raise awareness with other individuals that I work with, peers that don’t know what an MPN is. I’m constantly getting that: “What’s an MPN?”, so I love to educate other coworkers and also patients and family members on what MPNs are.”

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content